---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-08-17T21:02:25.727353'
end_time: '2026-08-17T21:13:36.756003'
duration_seconds: 671.03
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Loeys-Dietz Syndrome 1
  mondo_id: ''
  category: Mendelian
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    max_embedded_images: 8
citation_count: 18
reference_validation:
  total_references: 8
  verified: 8
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  quotes_checked: 2
  quotes_valid: 1
  quotes_unsupported: 1
  unsupported_quote_references:
  - DOI:10.1371/journal.pone.0279848
  relevance_assessed: 8
  on_topic: 2
  off_topic: 1
  off_topic_references:
  - DOI:10.1007/s00431-024-05456-z
  needs_review: true
  validator_version: 0.2.1
artifact_count: 1
artifact_sources:
  edison_answer_artifacts: 1
artifacts:
- filename: artifact-00.md
  path: Loeys-Dietz_Syndrome_1-deep-research-falcon_artifacts/artifact-00.md
  media_type: text/markdown
  source: edison_answer_artifacts
  data_storage_id: null
  description: Edison artifact artifact-00
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Loeys-Dietz Syndrome 1
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Loeys-Dietz Syndrome 1** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Loeys-Dietz Syndrome 1
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Loeys-Dietz Syndrome 1** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


# Loeys–Dietz Syndrome Type 1: Disease-Characteristics Report

**Scope and evidence note.** Loeys–Dietz syndrome type 1 (LDS1) means **TGFBR1-related** Loeys–Dietz syndrome. Many publications pool TGFBR1 with TGFBR2 or all LDS genotypes; such findings are labeled “all-LDS” or “mixed cohort” below and should not be interpreted as LDS1-specific frequencies. Evidence comes from aggregated disease resources, human cohorts, primary model studies, and trial registries—not individual electronic health records.

| Domain | LDS1 finding | Evidence type/strength | Ontology or identifier |
|---|---|---|---|
| Disease definition | Loeys-Dietz syndrome type 1 (LDS1) is the TGFBR1-related form of Loeys-Dietz syndrome, a syndromic heritable thoracic aortopathy/connective tissue disorder with aggressive aneurysm/dissection risk and extra-aortic craniofacial and skeletal features (laterza2019novelpathogenictgfbr1 pages 1-4, verstraeten2021loeys–dietzsyndrome pages 3-5, gallo2014angiotensinii–dependenttgfβ pages 1-2) | Human clinical + authoritative review; strong for disease entity | MONDO_0018954 (umbrella Loeys-Dietz syndrome); Mendelian disease |
| Causal gene | LDS1 is caused by heterozygous pathogenic variants in **TGFBR1** (transforming growth factor beta receptor 1) (OpenTargets Search: Loeys-Dietz syndrome-TGFBR1, laterza2019novelpathogenictgfbr1 pages 1-4, verstraeten2021loeys–dietzsyndrome pages 3-5, gallo2014angiotensinii–dependenttgfβ pages 1-2) | Human genetic evidence + curated disease-target association; strong | TGFBR1; Open Targets disease-target link to MONDO_0018954 |
| Inheritance | Typically **autosomal dominant**; many cases are **de novo** (~75%) and the remainder inherited (~25%), with variable expressivity (verstraeten2021loeys–dietzsyndrome pages 3-5) | Expert review summarizing clinical series; moderate-strong | Autosomal dominant inheritance |
| Variant spectrum | Variants are predominantly **missense substitutions in the kinase domain**; nonsense, frameshift, splice, and deletion variants also occur; germline origin (laterza2019novelpathogenictgfbr1 pages 1-4, verstraeten2021loeys–dietzsyndrome pages 3-5, gallo2014angiotensinii–dependenttgfβ pages 1-2) | Human genetic studies + review; strong for spectrum, limited LDS1-specific frequency data | Germline pathogenic/likely pathogenic variant |
| Main vascular phenotype | Early, progressive **aortic root aneurysm**, widespread arterial tortuosity, aneurysms/dissections throughout the arterial tree, and risk of rupture at relatively small diameters; mitral valve prolapse/regurgitation also common (laterza2019novelpathogenictgfbr1 pages 1-4, verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 7-8, gallo2014angiotensinii–dependenttgfβ pages 1-2) | Human clinical + expert management review + mouse model concordance; strong | HPO terms to consider: Aortic root dilatation, Arterial tortuosity, Aortic dissection, Mitral valve prolapse |
| Craniofacial phenotype | Characteristic features include **hypertelorism**, **bifid uvula/cleft palate**, and sometimes **craniosynostosis**; high-arched palate, micro/retrognathia may occur (verstraeten2021loeys–dietzsyndrome pages 5-6, verstraeten2021loeys–dietzsyndrome pages 7-8) | Expert review from established LDS authorities; moderate-strong | HPO terms to consider: Hypertelorism, Bifid uvula, Cleft palate, Craniosynostosis |
| Skeletal/musculoskeletal phenotype | Common findings include **pectus deformity, scoliosis, pes planus, joint hypermobility**, recurrent subluxations, **camptodactyly/club foot**, cervical spine instability, low bone density, and fracture risk (verstraeten2021loeys–dietzsyndrome pages 7-8) | Expert review; moderate-strong | HPO terms to consider: Pectus excavatum/carinatum, Scoliosis, Pes planus, Joint hypermobility, Camptodactyly, Talipes equinovarus |
| Core mechanism | TGFBR1 mutant cells show impaired response to exogenous TGF-β in vitro, but diseased aortic tissue shows **paradoxically increased SMAD2 phosphorylation and TGF-β target-gene output in vivo**, consistent with compensatory/secondary signaling overdrive during aneurysm progression (gallo2014angiotensinii–dependenttgfβ pages 8-9, gallo2014angiotensinii–dependenttgfβ pages 1-2, gallo2014angiotensinii–dependenttgfβ pages 2-4) | Primary mouse mechanistic study + review; strong mechanistic support with residual uncertainty about upstream trigger | GO terms to consider: TGF-beta receptor signaling pathway, SMAD protein signal transduction |
| Tissue pathology | Aortic wall pathology includes **elastic fiber fragmentation**, **collagen disorganization/excess or defective remodeling**, wall thickening, and altered extracellular matrix homeostasis (elendu2025geneticfactorsand pages 11-12, gallo2014angiotensinii–dependenttgfβ pages 8-9, gallo2014angiotensinii–dependenttgfβ pages 2-4, yang2024bioengineeredvasculargrafts pages 1-2) | Human pathology + primary model systems; strong | GO terms to consider: Extracellular matrix organization, Collagen fibril organization; UBERON: aorta |
| Cell types implicated | **Vascular smooth muscle cells** are central disease cells; evidence also supports roles for aortic root lineage-specific SMC populations and possibly inflammatory/CD45+ cells in signaling amplification (gallo2014angiotensinii–dependenttgfβ pages 8-9, yang2024bioengineeredvasculargrafts pages 1-2) | Primary mouse and human-cell modeling; moderate-strong | CL terms to consider: vascular smooth muscle cell, endothelial cell, leukocyte |
| Diagnosis | Diagnosis is established by compatible clinical features plus **molecular testing of TGFBR1**; current practice favors **multigene heritable thoracic aortic disease panels**, with CNV analysis if panel-negative (verstraeten2021loeys–dietzsyndrome pages 5-6) | Expert review/current practice; strong | Differential diagnoses include Marfan syndrome, vascular Ehlers-Danlos syndrome, arterial tortuosity syndrome, Shprintzen-Goldberg syndrome |
| Surveillance | Recommended surveillance includes **at least yearly echocardiography** and **head-to-pelvis MRA/CTA** at diagnosis, again at 1 year, then at least every 2–3 years or more often if warranted (verstraeten2021loeys–dietzsyndrome pages 8-9) | Expert management guidance from LDS specialists; strong | Imaging modalities: echocardiography, MRA, CTA |
| Medical treatment | Medical management emphasizes strict blood-pressure control; **ARBs such as losartan** are widely used, often with/against **beta-blockers**. In mouse LDS models, losartan reduced pathologic signaling and improved aortic outcomes (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 9-11, gallo2014angiotensinii–dependenttgfβ pages 8-9, gallo2014angiotensinii–dependenttgfβ pages 1-2) | Expert clinical practice + primary preclinical therapeutic evidence; moderate-strong | NCIT terms to consider: Losartan, Beta-Adrenergic Receptor Antagonist Therapy |
| Surgical treatment | **Prophylactic aortic root surgery** is considered at lower thresholds than many other aortopathies; for **LDS1/LDS2, ~4.0 cm** is a commonly cited adult threshold, individualized by growth rate, family history, and valve disease (verstraeten2021loeys–dietzsyndrome pages 8-9) | Expert management guidance; strong but individualized | NCIT terms to consider: Aortic Root Replacement, Valve-Sparing Aortic Root Replacement |
| Lifestyle/prevention | Avoid high-intensity isometric/contact activity and exercise to exhaustion; use caution with vasoconstrictive/stimulant medications. Genetic counseling and family screening are important secondary prevention strategies (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 9-11) | Expert guidance; moderate-strong | Prevention domains: secondary prevention, cascade genetic screening |
| Prognosis/natural history | Disease is lifelong and progressive, with cardiovascular disease the major cause of morbidity/mortality; vascular events can occur in infancy/childhood or adulthood and at small diameters, so ongoing surveillance is essential (verstraeten2021loeys–dietzsyndrome pages 7-8, gallo2014angiotensinii–dependenttgfβ pages 1-2) | Human clinical observation + expert review; strong | Chronic progressive disease course |
| Prevalence caveat | Robust **LDS1-specific prevalence** was not identified in retrieved sources; published estimates usually refer to **all Loeys-Dietz syndrome** (~1 in 100,000), so subtype-specific epidemiology should be treated as uncertain (elendu2025geneticfactorsand pages 11-12) | Review-level estimate; weak for LDS1-specific prevalence | Epidemiology caveat; no confirmed LDS1-only rate |
| Recent QoL/real-world burden | LDS-specific recent data are sparse and often mixed with other HTADs; available studies show reduced physical fitness, fatigue burden, and impaired work participation in mixed LDS cohorts, not LDS1-only samples (johansen2022educationandemployment pages 4-6, johansen2022educationandemployment pages 1-2, warninkkavelaars2024physicalfitnessin pages 1-2) | Mixed-cohort observational evidence; limited for LDS1 specificity | PROMIS Fatigue; Satisfaction With Life; disability/work participation |
| Key animal model | **Tgfbr1 M318R/+ knock-in mouse** recapitulates LDS vascular and craniofacial/skeletal phenotypes, unlike simple Tgfbr1 haploinsufficiency; supports pathogenic effect of mutant receptor protein rather than haploinsufficiency alone (gallo2014angiotensinii–dependenttgfβ pages 1-2, gallo2014angiotensinii–dependenttgfβ pages 2-4) | Primary in vivo model; strong | Mouse knock-in model |
| Key human cellular model | **hiPSC-derived vascular smooth muscle cell/bioengineered vascular graft model with TGFBR1 A230T** shows reduced mechanical strength, in vivo graft dilation, defective ECM gene expression, and decreased collagen hydroxylation (yang2024bioengineeredvasculargrafts pages 1-2) | Primary translational human model; strong | hiPSC-derived VSMC; bioengineered vascular graft model |
| Current trials landscape | Retrieved records included an **immunopathology** interventional study in genetically confirmed LDS (NCT05472519), but no retrieved **gene therapy/RNA therapy/cell therapy or proven disease-modifying LDS1-specific drug trial** (NCT05472519 chunk 1) | Clinical trial registry evidence; moderate | NCT05472519 |
| Evidence provenance | This entry is derived from **aggregated disease-level resources**, primary literature, model-system studies, and clinical-trial registries rather than individual EHR data (OpenTargets Search: Loeys-Dietz syndrome-TGFBR1, verstraeten2021loeys–dietzsyndrome pages 3-5, NCT05472519 chunk 1) | Evidence synthesis statement | Disease-level resource provenance |


*Table: This table provides a compact, knowledge-base-ready summary of Loeys-Dietz syndrome type 1 focused on confirmed TGFBR1-related findings, management-relevant features, and model systems. It also flags where evidence is only available for umbrella LDS or mixed cohorts rather than LDS1 specifically.*

## 1. Disease information

LDS1 is a rare, autosomal-dominant, syndromic heritable thoracic aortic disease caused by a heterozygous pathogenic variant in **TGFBR1**, encoding transforming growth factor-β receptor type I/ALK5. Its defining risk is progressive, often widespread arterial aneurysm, tortuosity, dissection, and rupture, accompanied variably by craniofacial, skeletal, cutaneous, ocular, pulmonary, gastrointestinal, and allergic manifestations. The same TGFBR1 variant can produce classic syndromic LDS or apparently nonsyndromic thoracic aortic disease, so absence of the classic facial triad does not exclude LDS1. Open Targets links TGFBR1 (ENSG00000106799) to umbrella LDS, supported by ClinGen and human literature including PMIDs **15731757, 16928994, 16799921, 25006744, and 26493799**. (OpenTargets Search: Loeys-Dietz syndrome-TGFBR1, laterza2019novelpathogenictgfbr1 pages 1-4, verstraeten2021loeys–dietzsyndrome pages 5-6)

**Identifiers and names**

- **Disease:** Loeys–Dietz syndrome type 1; TGFBR1-related Loeys–Dietz syndrome; LDS1; Loeys–Dietz syndrome, type I.
- **OMIM:** commonly designated **Loeys-Dietz syndrome 1, 609192**; causal gene **TGFBR1, 190181**.
- **MONDO:** retrieved Open Targets evidence used **MONDO:0018954** for umbrella Loeys–Dietz syndrome; a separate LDS1-specific MONDO identifier was not established in the retrieved evidence.
- **Orphanet:** Loeys–Dietz syndrome is represented at the umbrella level; subtype-specific coding varies by release.
- **ICD-10-CM:** no uniquely specific LDS1 code; coding generally uses congenital connective-tissue/aortic aneurysm manifestations. **ICD-11** includes Loeys–Dietz syndrome under rare developmental/connective-tissue disease, but local coding should be release-verified.
- **MeSH:** no consistently used LDS1-specific descriptor was verified; literature is indexed under Loeys–Dietz syndrome, aortic aneurysm, and connective-tissue diseases.

The original receptor-related LDS literature is indexed by PMID **15731757** (2005) and subsequent clinical expansion by PMID **16928994** (2006). The retrieved 2019 report illustrates diagnostic under-recognition: a 47-year-old with the novel **TGFBR1 NM_004612.2:c.1225T>G, p.(Trp409Gly)** first presented with carotid dissection and middle cerebral artery occlusion after sports activity despite mild systemic findings (published October 2019; DOI: https://doi.org/10.1016/j.ejmg.2019.103727). (OpenTargets Search: Loeys-Dietz syndrome-TGFBR1, laterza2019novelpathogenictgfbr1 pages 1-4)

## 2. Etiology, risk, protection, and gene–environment interaction

### Causal factor

The primary cause is a **constitutional/germline heterozygous pathogenic TGFBR1 variant**. Most disease-associated substitutions affect conserved residues in the intracellular serine/threonine kinase domain. Nonsense, frameshift, splice-altering, and deletion variants occur but are less common. In vitro, many mutant receptors have reduced canonical signaling capacity; the pathogenic effect is not adequately described as simple haploinsufficiency because Tgfbr1-null heterozygous mice lack the LDS vascular phenotype whereas missense knock-in mice reproduce it. (verstraeten2021loeys–dietzsyndrome pages 3-5, gallo2014angiotensinii–dependenttgfβ pages 1-2, gallo2014angiotensinii–dependenttgfβ pages 2-4)

### Risk factors

- **Genetic:** pathogenic/likely pathogenic TGFBR1 variant; affected first-degree relative; de novo variant. Approximately **75%** of LDS cases were described as de novo and **25%** inherited in the authoritative review, although this estimate is not from an LDS1-only population. Expressivity is broad, and a mildly affected parent may have a severely affected child. Modifier genes are inferred but no validated clinical modifier has been established. (verstraeten2021loeys–dietzsyndrome pages 3-5, verstraeten2021loeys–dietzsyndrome pages 5-6)
- **Hemodynamic/environmental:** hypertension, heavy isometric exertion, contact trauma, exercise to exhaustion, and stimulant/vasoconstrictor exposure can increase arterial wall stress. The 2019 cerebrovascular case following sports activity is suggestive but does not prove causation. Pregnancy and the postpartum period plausibly increase risk through hemodynamic and hormonal stress, but robust LDS1-specific event rates were unavailable. (laterza2019novelpathogenictgfbr1 pages 1-4, verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 9-11)
- **Age/sex:** disease can manifest from infancy through adulthood. No reliable LDS1-specific sex difference, ethnic predisposition, or age-specific incidence was identified.

### Protective factors

No genetic protective allele is clinically validated. Practical protection is secondary/tertiary: early molecular diagnosis, lifelong imaging, strict blood-pressure control, avoidance of high-strain activity, and timely prophylactic surgery. Losartan was strongly protective in LDS mouse models, but human LDS1 randomized efficacy data remain insufficient. (verstraeten2021loeys–dietzsyndrome pages 8-9, gallo2014angiotensinii–dependenttgfβ pages 8-9)

There is no infectious cause and no established toxin, diet, smoking, alcohol, pollution, or occupational exposure that causes LDS1. These exposures may modify general cardiovascular risk but have not been quantified as LDS1 gene–environment interactions.

## 3. Phenotypes

Frequencies below are qualitative unless a defensible all-LDS estimate was retrieved.

- **Aortic-root dilatation/aneurysm**—clinical sign, often silent; congenital, pediatric, or adult onset; progressive and potentially severe. Dissection has occurred at adult aortic diameters as small as **3.7 cm**. Suggested HPO: *Aortic root dilatation; Thoracic aortic aneurysm; Aortic dissection*. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 7-8)
- **Diffuse arterial tortuosity, aneurysm, dissection, or rupture**—particularly head/neck vessels but potentially subclavian, cerebral, coronary, mesenteric, celiac, hepatic, iliac, and the entire aorta. Events have been reported as early as **3 months** in all-LDS experience. HPO: *Arterial tortuosity; Arterial aneurysm; Carotid artery dissection; Intracranial aneurysm*. (laterza2019novelpathogenictgfbr1 pages 1-4, verstraeten2021loeys–dietzsyndrome pages 7-8)
- **Cardiac/valvular:** mitral-valve prolapse/regurgitation; less consistently bicuspid aortic valve, patent ductus arteriosus, or atrial septal defect. HPO: *Mitral valve prolapse; Mitral regurgitation; Bicuspid aortic valve; Patent ductus arteriosus; Atrial septal defect*. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 7-8)
- **Craniofacial:** hypertelorism, bifid/broad/long uvula, cleft palate, high-arched palate, craniosynostosis, malar flattening, micrognathia/retrognathia, and dental crowding. Congenital, with severity ranging from subtle uvular change to major craniosynostosis/clefting. HPO: *Hypertelorism; Bifid uvula; Cleft palate; High palate; Craniosynostosis; Micrognathia*. (verstraeten2021loeys–dietzsyndrome pages 7-8)
- **Musculoskeletal:** pectus deformity, scoliosis, arachnodactyly, pes planus, joint hypermobility/subluxation, congenital hip dislocation, camptodactyly, clubfoot, hypotonia, cervical-spine anomalies/instability, low bone density, and fracture susceptibility. Across all LDS, structural cervical anomalies were estimated at **~33%**, and cervical instability at **≥50%**, particularly with severe craniofacial disease. HPO: *Pectus excavatum/carinatum; Scoliosis; Arachnodactyly; Pes planus; Generalized joint hypermobility; Camptodactyly; Talipes equinovarus; Cervical spine instability; Reduced bone mineral density*. (verstraeten2021loeys–dietzsyndrome pages 7-8)
- **Neurologic/neuroradiologic:** dural ectasia, rare Chiari I malformation, hydrocephalus, headache/migraine, and cerebrovascular events. Up to **50%** of all-LDS patients were reported to experience recurrent headache/migraine. Cognition is usually unaffected. HPO: *Dural ectasia; Chiari malformation type I; Hydrocephalus; Migraine*. (verstraeten2021loeys–dietzsyndrome pages 6-7, verstraeten2021loeys–dietzsyndrome pages 9-11)
- **Ocular:** myopia, blue/dusky sclera, exotropia/strabismus, cataract, retinal detachment, and retinal tortuosity. **Ectopia lentis is generally absent**, helping distinguish LDS from Marfan syndrome. HPO: *Myopia; Blue sclerae; Strabismus; Retinal detachment*. (verstraeten2021loeys–dietzsyndrome pages 9-11)
- **Respiratory:** pneumothorax, restrictive disease secondary to skeletal deformity, asthma/allergic obstruction, emphysema, sleep apnea, and airway compression from severe pulmonary-artery enlargement. HPO: *Spontaneous pneumothorax; Restrictive lung disease; Asthma; Obstructive sleep apnea*. (verstraeten2021loeys–dietzsyndrome pages 9-11)
- **Growth/feeding/GI/allergy:** infantile feeding difficulty or failure to thrive, constipation, food/environmental allergy, elevated IgE, asthma, eczema, and eosinophilic gastrointestinal disease occur in the broader LDS spectrum. LDS1-specific frequencies were not retrieved.
- **Cutaneous:** translucent/velvety skin, easy bruising, widened or atrophic scars, and striae may occur; generally less tissue fragility than vascular Ehlers–Danlos syndrome.

**Quality of life.** LDS1-only patient-reported data are sparse. In a 2024 mixed study of 42 children—36 Marfan and only 6 LDS—mean treadmill time-to-exhaustion was **3.1 SD below norms**, and self-reported fatigue explained **48–49%** of fitness variance (published March 2024; DOI: https://doi.org/10.1007/s00431-024-05456-z). (warninkkavelaars2024physicalfitnessin pages 1-2)

A Norwegian mixed cohort included 33 adults with LDS and 17 with vascular EDS: **66%** received disability benefits, **42%** had full-time disability pension, and median work cessation was **41 years**; 80% reported chronic pain. These figures cannot be assigned specifically to LDS1. The abstract states that employed participants were “less fatigued…had less sleep problems and higher satisfaction with life” (published December 2022; DOI: https://doi.org/10.1371/journal.pone.0279848). (johansen2022educationandemployment pages 4-6, johansen2022educationandemployment pages 1-2, johansen2022educationandemployment pages 8-9)

## 4. Genetic and molecular information

**TGFBR1** comprises nine exons and encodes a transmembrane serine/threonine kinase receptor. The retrieved 2019 report noted 84 TGFBR1 mutations in HGMD at that time, but this is obsolete and not a current pathogenic-variant count. Pathogenic variants are germline and usually heterozygous. ClinVar classification should be applied variant by variant under ACMG/AMP criteria; a VUS alone does not establish LDS1. (laterza2019novelpathogenictgfbr1 pages 1-4)

Pathogenic LDS1 alleles are expected to be absent or extremely rare in population databases such as gnomAD; no universal allele frequency can be assigned. Missense kinase-domain variants predominate. The best-supported functional model combines impaired receptor output under controlled ligand stimulation with chronic compensation, ligand overproduction, and paradoxical excess pathway output in diseased tissue. A blanket “gain-of-function” or “loss-of-function” annotation is therefore misleading. (verstraeten2021loeys–dietzsyndrome pages 3-5, gallo2014angiotensinii–dependenttgfβ pages 8-9, gallo2014angiotensinii–dependenttgfβ pages 1-2)

No reproducible LDS1 modifier gene, founder mutation, anticipation mechanism, disease-specific methylation signature, or recurrent chromosomal abnormality is established. Large deletions/CNVs are possible but much less characteristic than sequence variants. Somatic mutation is not the usual origin. Biallelic TGFBR1-related profound connective-tissue disease has been reported, but classic LDS1 is dominant and monoallelic.

Suggested annotations: **HGNC:11772 (TGFBR1)**; protein TGF-β receptor type I/ALK5; GO concepts *transforming growth factor beta receptor signaling pathway*, *SMAD protein signal transduction*, and *transmembrane receptor protein serine/threonine kinase activity*.

## 5. Environmental and lifestyle information

Environmental exposure is not etiologic. Management treats mechanical load as a modifier: avoid collision sports, intense isometric exercise, heavy lifting, and exercise to exhaustion; favor individualized moderate dynamic activity after cardiovascular assessment. Avoid tobacco and uncontrolled hypertension as general vascular precautions, although LDS1-specific attributable-risk estimates are unavailable. Decongestants, stimulants, and vasoconstrictive migraine drugs require caution. No pathogen, vector, vaccine, toxin-removal program, or infectious prophylaxis is LDS1-specific. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 9-11)

## 6. Mechanism and pathophysiology

**Causal chain:** germline TGFBR1 variant → defective receptor kinase signaling in susceptible mesenchymal/vascular lineages → altered vascular smooth-muscle-cell differentiation, organization, and contractility → compensatory TGF-β1 production and progressively increased pSMAD2/3/target-gene activity in vivo → dysregulated ECM synthesis/remodeling, collagen modification, elastin fragmentation, proteoglycan accumulation, and wall thickening → reduced arterial tensile strength/compliance → progressive dilation, tortuosity, aneurysm, dissection, and rupture. Craniofacial, skeletal, palatal, pulmonary, and immune phenotypes reflect TGF-β’s developmental and homeostatic roles in other tissues. (elendu2025geneticfactorsand pages 11-12, gallo2014angiotensinii–dependenttgfβ pages 8-9, gallo2014angiotensinii–dependenttgfβ pages 1-2, yang2024bioengineeredvasculargrafts pages 1-2)

The 2014 knock-in study’s abstract states that aortic-wall signaling showed “**progressive upregulation of Smad2 phosphorylation and TGF-β target gene output**,” paralleling aneurysm progression (J Clin Invest, January 2014; DOI: https://doi.org/10.1172/JCI69666). Tgfbr1^M318R/+ mice developed enlarged roots, accelerated growth, elastin breaks, excessive collagen, tortuosity, dissection, and shortened survival, whereas simple Tgfbr1 haploinsufficiency did not. Approximately **60% of mouse deaths** showed hemothorax or hemopericardium. Losartan protection correlated with reduced pSmad2 and TGF-β1, while hemodynamically comparable propranolol had only a modest growth effect and did not preserve wall architecture. (gallo2014angiotensinii–dependenttgfβ pages 8-9, gallo2014angiotensinii–dependenttgfβ pages 1-2, gallo2014angiotensinii–dependenttgfβ pages 2-4)

A major 2024 development used gene-edited and patient-derived hiPSC vascular smooth-muscle cells carrying **TGFBR1 p.Ala230Thr** in bioengineered grafts implanted into nude-rat carotid arteries. Mutant grafts had lower burst pressure and suture-retention strength and dilated in vivo. Spatial transcriptomics identified defective ECM-gene expression; tissue assays showed decreased collagen hydroxylation and disorganized smooth muscle. The authors’ abstract concludes that the work “**highlighted the role of reduced collagen modifying enzyme activity in human TAA formation**” (Science Translational Medicine, 8 May 2024; DOI: https://doi.org/10.1126/scitranslmed.adg6298). (yang2024bioengineeredvasculargrafts pages 1-2)

**Cell/ontology suggestions:** vascular smooth-muscle cell (CL), endothelial cell (CL), fibroblast/myofibroblast (CL), leukocyte/CD45-positive immune cell (CL); aorta and aortic root (UBERON); extracellular matrix, plasma membrane receptor complex, cytoplasm, and nucleus (GO cellular components). Relevant biological processes include ECM organization, collagen fibril organization, elastic-fiber assembly, smooth-muscle contraction, response to mechanical stimulus, and TGF-β receptor signaling. No validated LDS1 metabolomic, lipidomic, single-cell atlas, or diagnostic multi-omics signature is currently established.

## 7. Anatomical structures affected

The **primary organ system** is cardiovascular: aortic root, ascending/descending thoracic and abdominal aorta, and medium-to-large arteries from head to pelvis. Secondary sites include mitral/aortic valves, pulmonary artery, cerebral and cervical arteries, coronary and visceral branches. Other systems include skull/sutures, palate/uvula, cervical and thoracolumbar spine, thoracic cage, joints, long bones/digits, skin, eyes/retina, dura, lungs/airways, and gastrointestinal tract. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 7-8, verstraeten2021loeys–dietzsyndrome pages 9-11)

At tissue level, the arterial media and adventitia are central, particularly lineage-specific aortic smooth-muscle populations derived from second heart field and neural crest. Relevant subcellular sites are the plasma membrane TGFBR complex, cytoplasmic SMAD signaling machinery, nucleus, and extracellular collagen/elastin matrix. Disease is generally systemic and bilateral rather than lateralized; an individual aneurysm or dissection can be anatomically asymmetric.

## 8. Temporal development

LDS1 is congenital in genetic origin and lifelong. Craniofacial, palatal, foot, and skeletal abnormalities may be evident prenatally or neonatally. Aortic enlargement can begin in infancy or childhood but may remain clinically silent until adult dissection or stroke. Progression is chronic and highly variable, with abrupt episodic complications superimposed on progressive arteriopathy. No remission is expected. (laterza2019novelpathogenictgfbr1 pages 1-4, verstraeten2021loeys–dietzsyndrome pages 7-8)

Critical intervention windows are: diagnosis before the first vascular event; serial imaging during somatic growth; intensified assessment during rapid aortic enlargement; preconception and pregnancy/postpartum surveillance; and close follow-up after dissection or surgery. After type-B dissection, expert guidance recommends imaging at **7–14 days and 1, 3, 6, and 12 months**, then annually if stable. (verstraeten2021loeys–dietzsyndrome pages 8-9)

## 9. Inheritance and population

Inheritance is autosomal dominant, with a **50% transmission probability per pregnancy** for a heterozygous parent. Penetrance is high but may be incomplete and is age-dependent; expressivity is markedly variable. Anticipation is unproven. Parental mosaicism and germline mosaicism are possible explanations for recurrence after an apparently de novo event but are not quantified. Consanguinity is not relevant to ordinary monoallelic LDS1. (verstraeten2021loeys–dietzsyndrome pages 3-5, verstraeten2021loeys–dietzsyndrome pages 5-6)

The estimated prevalence often quoted for **all LDS is approximately 1 in 100,000**, but this is not a measured LDS1 prevalence and may reflect underdiagnosis. Reliable incidence, carrier frequency, founder effects, geographic clustering, ethnic enrichment, and sex ratio were not identified. LDS occurs globally and in all sexes. (elendu2025geneticfactorsand pages 11-12)

## 10. Diagnostics

Diagnosis combines phenotype, family history, vascular imaging, and identification of a heterozygous pathogenic/likely pathogenic **TGFBR1** variant.

1. **Clinical assessment:** three-generation pedigree; examination for hypertelorism, uvular/palatal anomaly, craniosynostosis, pectus/scoliosis, joint laxity or contracture, clubfoot, translucent skin, bruising, and allergic/GI manifestations.
2. **Imaging:** baseline transthoracic echocardiography for root/ascending aorta and valves; contrast CTA or MRA from head through pelvis to detect tortuosity, aneurysm, and dissection. Flexion–extension cervical radiographs assess instability; CT evaluates suspected craniosynostosis; DEXA is reasonable for low density/fracture risk. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 7-8)
3. **Genetics:** a comprehensive heritable thoracic aortic disease panel is preferred over serial single-gene testing because of phenotypic overlap. Panels should include at least TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB2, TGFB3, FBN1, SKI, COL3A1, ACTA2, MYH11, MYLK, PRKG1, SLC2A10, EFEMP2, FLNA, and BGN as locally appropriate. Add deletion/duplication analysis because some panels incompletely detect CNVs. WES/WGS is appropriate when panel testing is negative or the presentation is atypical. CMA/karyotype/FISH, mitochondrial sequencing, and repeat-expansion testing are not routine unless another diagnosis is suspected. (verstraeten2021loeys–dietzsyndrome pages 5-6)
4. **Biomarkers/omics:** no validated blood, protein, metabolite, liquid-biopsy, or epigenomic diagnostic test replaces molecular testing and imaging.

**Differential diagnosis:** Marfan syndrome—ectopia lentis and FBN1, usually less diffuse tortuosity; vascular EDS—COL3A1, greater tissue/organ fragility and rupture without prior dilation; Shprintzen–Goldberg syndrome—SKI plus developmental delay; arterial tortuosity syndrome—biallelic SLC2A10 with generalized tortuosity and stenoses; congenital contractural arachnodactyly—FBN2, crumpled ears and contractures without aggressive aneurysm; cutis laxa—marked loose skin/emphysema; and nonsyndromic HTAD. (verstraeten2021loeys–dietzsyndrome pages 6-7, verstraeten2021loeys–dietzsyndrome pages 5-6)

Cascade testing is recommended for relatives. Prenatal diagnosis and preimplantation genetic testing are feasible once the familial variant is known. LDS1 is not part of routine newborn biochemical screening.

## 11. Outcome and prognosis

Cardiovascular disease is the major source of morbidity and mortality. Prognosis depends on genotype/variant context, maximum and growth-rate of arterial dimensions, prior dissection, family history, arterial distribution, blood pressure, valve disease, and access to surveillance and prophylactic repair. Exact 5- or 10-year LDS1 survival and life expectancy are not established. Historical descriptions of early rupture should not be translated directly to modern managed patients. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 7-8)

Morbidity includes repeated imaging and operations, chronic pain, fatigue, reduced physical participation, orthopedic disability, allergy/GI disease, and psychosocial distress. Surgery reduces risk in the replaced segment but does **not** eliminate distal dissection or new aneurysm, so lifelong surveillance continues. (verstraeten2021loeys–dietzsyndrome pages 9-11, johansen2022educationandemployment pages 4-6, warninkkavelaars2024physicalfitnessin pages 1-2)

No validated circulating prognostic biomarker exists. Rapid growth, family dissection at small diameter, severe craniofacial features/arterial tortuosity, and prior vascular event favor a more aggressive strategy, although phenotype–risk correlations are imperfect.

## 12. Treatment

There is no curative or FDA-approved LDS1-specific molecular therapy.

- **Antihypertensive pharmacotherapy:** an angiotensin-II receptor blocker—commonly losartan—and/or a β-blocker is used to reduce hemodynamic stress. The specialist review describes losartan targets of **2 mg/kg/day in children** and **at least 100 mg/day in adults** as personal practice, not trial-validated universal dosing. Monitor blood pressure, renal function, potassium, bradycardia, and fatigue. ARBs are contraindicated during pregnancy. Suggested NCIT concepts: *Losartan; Angiotensin II Receptor Antagonist; Beta-Adrenergic Receptor Antagonist*. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 9-11)
- **Surgery:** prophylactic valve-sparing aortic-root replacement is often preferred. For adults with LDS1/LDS2, expert guidance commonly considers surgery around **4.0 cm**, individualized downward or upward by body size, growth rate, family history, variant severity, valve regurgitation, and surgical expertise. Rapidly enlarging or markedly disproportionate visceral/iliac aneurysms also merit intervention. Suggested NCIT concepts: *Aortic Root Replacement; Valve-Sparing Aortic Root Replacement; Vascular Surgery*. (verstraeten2021loeys–dietzsyndrome pages 8-9)
- **Supportive care:** physical therapy for hypotonia/hypermobility; orthopedic management of scoliosis, cervical instability, and clubfoot; calcium/vitamin-D adequacy and bone-health assessment; standard craniosynostosis/cleft-palate, ophthalmic, pulmonary, allergy, GI, dental, pain, and psychosocial care. (verstraeten2021loeys–dietzsyndrome pages 7-8, verstraeten2021loeys–dietzsyndrome pages 9-11)
- **Rehabilitation:** individualized low-to-moderate dynamic exercise may counter deconditioning and fatigue, but data are mainly mixed Marfan/LDS cohorts rather than LDS1 trials. (warninkkavelaars2024physicalfitnessin pages 1-2)
- **Advanced therapeutics:** no retrieved clinical gene-replacement, CRISPR, cell, mRNA, ASO, or siRNA therapy exists for LDS1. The 2024 collagen-modification work is mechanistic, not a clinical treatment. (yang2024bioengineeredvasculargrafts pages 1-2)

**Trial landscape:** NCT05472519 (I-LoDiS; France; completed June 2023; actual n=60) compared genetically confirmed TGFBR1/TGFBR2 LDS with controls, measuring circulating T-follicular-helper cells, intracellular pSMAD2/3, allergic/infectious disease, and vascular/morphoskeletal complications. It was a blood-sampling immunopathology study, not a therapeutic drug trial. (NCT05472519 chunk 1)

## 13. Prevention

Primary prevention of the germline disorder is not possible after conception. Reproductive options include genetic counseling, donor gametes, PGT-M, and prenatal diagnosis. Secondary prevention consists of cascade testing and presymptomatic vascular imaging. Tertiary prevention comprises blood-pressure control, avoidance of high-strain activities and tobacco, serial whole-arterial-tree imaging, pregnancy planning, prompt assessment of acute chest/back/abdominal/neurologic symptoms, and prophylactic repair. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 9-11)

Recommended expert surveillance includes echocardiography **at least annually**, more often with active enlargement, and head-to-pelvis MRA/CTA at diagnosis, again after one year, then at least every **2–3 years** if stable. These intervals must be individualized. There is no applicable vaccine, infection-control program, population-wide screening program, or preventive dietary supplement beyond ordinary bone/cardiovascular health. (verstraeten2021loeys–dietzsyndrome pages 8-9)

## 14. Other species and natural disease

No well-established naturally occurring veterinary LDS1 equivalent was identified in the retrieved evidence. TGFBR1 is evolutionarily conserved in mammals, but experimental engineered disease should not be labeled natural animal disease. There is no transmission or zoonotic potential. Relevant taxa for experimental work are **Mus musculus** (NCBI Taxonomy 10090) and **Rattus norvegicus** (10116). Breed-specific/VBO associations and an OMIA natural-disease entry were not established.

## 15. Model organisms and experimental systems

- **Tgfbr1^M318R/+ knock-in mouse:** mammalian germline knock-in; reproduces progressive aortic-root enlargement, elastin fragmentation, collagen accumulation, arterial tortuosity, dissection, early death, and craniofacial/skeletal findings. It is useful for receptor biology and drug testing. Limitation: mouse size, lifespan, hemodynamics, and developmental lineages differ from humans. (gallo2014angiotensinii–dependenttgfβ pages 1-2, gallo2014angiotensinii–dependenttgfβ pages 2-4)
- **Tgfbr1 haploinsufficient mouse:** approximately 50% transcript reduction but no comparable cardiovascular phenotype; a valuable negative model showing that simple dosage loss is insufficient. (gallo2014angiotensinii–dependenttgfβ pages 2-4)
- **Patient and isogenic hiPSC-derived VSMCs:** model lineage-specific cellular defects and permit genetic correction controls. Limitation: two-dimensional cultures lack full vascular architecture and hemodynamic loading. (yang2024bioengineeredvasculargrafts pages 1-2)
- **2024 bioengineered vascular graft:** TGFBR1 p.Ala230Thr patient/isogenic VSMCs formed grafts implanted in nude-rat carotids, combining human genotype with in-vivo mechanical stress. It reproduced dilation, weak mechanics, defective ECM transcription, reduced collagen hydroxylation, and impaired contraction. Limitations include an ectopic carotid location, immunodeficient host, engineered tissue, and concentration on one variant. (yang2024bioengineeredvasculargrafts pages 1-2)

## Current expert interpretation and major evidence gaps

The most defensible current model is not simply “too little” or “too much” TGF-β. TGFBR1 variants impair receptor function in controlled cellular assays, while chronic, cell-nonautonomous compensation produces increased ligand/pSMAD signaling in the diseased postnatal vessel. The 2024 human graft study shifts attention downstream toward defective collagen modification and biomechanics, offering a more direct bridge from receptor genotype to wall failure. (gallo2014angiotensinii–dependenttgfβ pages 8-9, gallo2014angiotensinii–dependenttgfβ pages 1-2, yang2024bioengineeredvasculargrafts pages 1-2)

The principal gaps are LDS1-specific prevalence and natural-history estimates, prospective pregnancy data, variant-level risk models, randomized ARB/β-blocker trials, validated circulating biomarkers, representative single-cell/spatial atlases of human aorta, and disease-specific quality-of-life and rehabilitation trials. Consequently, current real-world care remains multidisciplinary and prevention-oriented: molecular confirmation, complete arterial imaging, strict blood-pressure management, tailored activity, and timely surgery.

References

1. (laterza2019novelpathogenictgfbr1 pages 1-4): Domenico Laterza, Marco Ritelli, Andrea Zini, Marina Colombi, Maria Luisa Dell'Acqua, Laura Vandelli, Guido Bigliardi, Luca Verganti, Stefano Vallone, Chiara Vincenzi, Francesca Rosafio, Ludovico Ciolli, Olga Calabrese, Paolo Frigio Nichelli, and Livio Picchetto. Novel pathogenic tgfbr1 and smad3 variants identified after cerebrovascular events in adult patients with loeys-dietz syndrome. European journal of medical genetics, 62:103727, Oct 2019. URL: https://doi.org/10.1016/j.ejmg.2019.103727, doi:10.1016/j.ejmg.2019.103727. This article has 18 citations and is from a peer-reviewed journal.

2. (verstraeten2021loeys–dietzsyndrome pages 3-5): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

3. (gallo2014angiotensinii–dependenttgfβ pages 1-2): Elena M. Gallo, David C. Loch, Jennifer P. Habashi, Juan F. Calderon, Yichun Chen, Djahida Bedja, Christel van Erp, Elizabeth E. Gerber, Sarah J. Parker, Kimberly Sauls, Daniel P. Judge, Sara K. Cooke, Mark E. Lindsay, Rosanne Rouf, Loretha Myers, Colette M. ap Rhys, Kathleen C. Kent, Russell A. Norris, David L. Huso, and Harry C. Dietz. Angiotensin ii–dependent tgf-β signaling contributes to loeys-dietz syndrome vascular pathogenesis. Journal of Clinical Investigation, 124(1):448-460, Dec 2014. URL: https://doi.org/10.1172/jci69666, doi:10.1172/jci69666. This article has 325 citations and is from a highest quality peer-reviewed journal.

4. (OpenTargets Search: Loeys-Dietz syndrome-TGFBR1): Open Targets Query (Loeys-Dietz syndrome-TGFBR1, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

5. (verstraeten2021loeys–dietzsyndrome pages 8-9): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

6. (verstraeten2021loeys–dietzsyndrome pages 7-8): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

7. (verstraeten2021loeys–dietzsyndrome pages 5-6): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

8. (gallo2014angiotensinii–dependenttgfβ pages 8-9): Elena M. Gallo, David C. Loch, Jennifer P. Habashi, Juan F. Calderon, Yichun Chen, Djahida Bedja, Christel van Erp, Elizabeth E. Gerber, Sarah J. Parker, Kimberly Sauls, Daniel P. Judge, Sara K. Cooke, Mark E. Lindsay, Rosanne Rouf, Loretha Myers, Colette M. ap Rhys, Kathleen C. Kent, Russell A. Norris, David L. Huso, and Harry C. Dietz. Angiotensin ii–dependent tgf-β signaling contributes to loeys-dietz syndrome vascular pathogenesis. Journal of Clinical Investigation, 124(1):448-460, Dec 2014. URL: https://doi.org/10.1172/jci69666, doi:10.1172/jci69666. This article has 325 citations and is from a highest quality peer-reviewed journal.

9. (gallo2014angiotensinii–dependenttgfβ pages 2-4): Elena M. Gallo, David C. Loch, Jennifer P. Habashi, Juan F. Calderon, Yichun Chen, Djahida Bedja, Christel van Erp, Elizabeth E. Gerber, Sarah J. Parker, Kimberly Sauls, Daniel P. Judge, Sara K. Cooke, Mark E. Lindsay, Rosanne Rouf, Loretha Myers, Colette M. ap Rhys, Kathleen C. Kent, Russell A. Norris, David L. Huso, and Harry C. Dietz. Angiotensin ii–dependent tgf-β signaling contributes to loeys-dietz syndrome vascular pathogenesis. Journal of Clinical Investigation, 124(1):448-460, Dec 2014. URL: https://doi.org/10.1172/jci69666, doi:10.1172/jci69666. This article has 325 citations and is from a highest quality peer-reviewed journal.

10. (elendu2025geneticfactorsand pages 11-12): Chukwuka Elendu, Tochukwu R. Nzeako, Nwachukwu O. Nwachukwu, Kenneth N. Akpa, Raymond A. Omiko, Petra S. Ayobami-Ojo, Uguru W. Orji, Vivian C. Nwankwo, Kingsley C. Amaefule, Chiamaka S. Chima, Nwafor W. Chika, John O. Olukorode, Praise O. Oloyede, David M. Falade, Temiloluwa E. Fayemi, Chisom P. Ezeamaku-Humphrey, Roshni R. Vansh, Tobechukwu M.O. Enaholo, Lordsfavour I. Anukam, and Osita M. Chukwuneke. Genetic factors and management strategies in aortic health: a literature review of inherited aortopathy. Annals of Medicine and Surgery, 87:598-615, Dec 2024. URL: https://doi.org/10.1097/ms9.0000000000002969, doi:10.1097/ms9.0000000000002969. This article has 9 citations.

11. (yang2024bioengineeredvasculargrafts pages 1-2): Ying Yang, Hao Feng, Ying Tang, Zhenguo Wang, Ping Qiu, Xihua Huang, Lin Chang, Jifeng Zhang, Yuqing Eugene Chen, Dogukan Mizrak, and Bo Yang. Bioengineered vascular grafts with a pathogenic tgfbr1 variant model aneurysm formation in vivo and reveal underlying collagen defects. Science Translational Medicine, May 2024. URL: https://doi.org/10.1126/scitranslmed.adg6298, doi:10.1126/scitranslmed.adg6298. This article has 17 citations and is from a highest quality peer-reviewed journal.

12. (verstraeten2021loeys–dietzsyndrome pages 9-11): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

13. (johansen2022educationandemployment pages 4-6): Heidi Johansen, Gry Velvin, and Ingeborg B. Lidal. Education and employment status among adults with loeys-dietz syndrome and vascular ehlers-danlos syndrome in norway, a questionnaire based study. PLOS ONE, 17:e0279848, Dec 2022. URL: https://doi.org/10.1371/journal.pone.0279848, doi:10.1371/journal.pone.0279848. This article has 4 citations and is from a peer-reviewed journal.

14. (johansen2022educationandemployment pages 1-2): Heidi Johansen, Gry Velvin, and Ingeborg B. Lidal. Education and employment status among adults with loeys-dietz syndrome and vascular ehlers-danlos syndrome in norway, a questionnaire based study. PLOS ONE, 17:e0279848, Dec 2022. URL: https://doi.org/10.1371/journal.pone.0279848, doi:10.1371/journal.pone.0279848. This article has 4 citations and is from a peer-reviewed journal.

15. (warninkkavelaars2024physicalfitnessin pages 1-2): Jessica Warnink-Kavelaars, Lisanne E. de Koning, Annelies E. van der Hulst, Annemieke I. Buizer, Nicole Poissonnier, Laura E. Wijninga, Leonie A. Menke, Laura Muiño Mosquera, Lies Rombaut, and Raoul H. H. Engelbert. Physical fitness in children with marfan and loeys-dietz syndrome: associations between cardiovascular parameters, systemic manifestations, fatigue, and pain. European Journal of Pediatrics, 183:2421-2429, Mar 2024. URL: https://doi.org/10.1007/s00431-024-05456-z, doi:10.1007/s00431-024-05456-z. This article has 4 citations and is from a peer-reviewed journal.

16. (NCT05472519 chunk 1):  Immunopathology of Loeys-Dietz Syndrome. Hospices Civils de Lyon. 2022. ClinicalTrials.gov Identifier: NCT05472519

17. (verstraeten2021loeys–dietzsyndrome pages 6-7): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

18. (johansen2022educationandemployment pages 8-9): Heidi Johansen, Gry Velvin, and Ingeborg B. Lidal. Education and employment status among adults with loeys-dietz syndrome and vascular ehlers-danlos syndrome in norway, a questionnaire based study. PLOS ONE, 17:e0279848, Dec 2022. URL: https://doi.org/10.1371/journal.pone.0279848, doi:10.1371/journal.pone.0279848. This article has 4 citations and is from a peer-reviewed journal.

## Artifacts

- [Edison artifact artifact-00](Loeys-Dietz_Syndrome_1-deep-research-falcon_artifacts/artifact-00.md)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 8 |
| Resolved | 8 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| Quoted claims checked | 2 |
| Quoted claims found in source | 1 |
| Quoted claims **not** found in source | 1 |
| References weighed for topical relevance | 8 |
| On topic | 2 |
| Off topic | 1 |

### Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked *abstract only* below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

- `DOI:10.1371/journal.pone.0279848` *(abstract only)*: "less fatigued…had less sleep problems and higher satisfaction with life"
  - closest text in source: "Full-time employed and students were younger (p = 0.014), less fatigued (p = 0.035), had less sleep problems (p = 0.028) and higher satisfaction with life (p<0.001) than those who received disability pension"

### References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

- `DOI:10.1007/s00431-024-05456-z` (5 mentions) - Physical fitness in children with Marfan and Loeys-Dietz syndrome: associations between cardiovascular parameters, systemic manifestations, fatigue, and pain
  - shared terms: aortic, tissue

Weighed against this report's own most characteristic terms: `disease`, `dietzsyndrome`, `clinical`, `genetic`, `variant`, `gene`, `vascular`, `lds1`, `model`, `type`, `tgfbr1`, `human`, `risk`, `phenotype`, `aortic`, `arterial`, `include`, `tissue`, `receptor`, `molecular`.